Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Experience-informed interpretation of contrast-enhanced CT for parathyroid localization in Sestamibi-Negative Primary Hyperparathyroidism.

Irish journal of medical science·2026

Same author

Tumor microenvironment-mediated interactions between macrophages and cancer cells define immunoregulatory transcriptional programs.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Same author

Myeloid Cell-Derived Thrombospondin-1 Mediates Anti-Metastatic Effects of Histamine Dihydrochloride in B16 Melanoma.

ImmunoTargets and therapy·2026

Same author

NRF2 activation by myeloid cell-derived oxidative stress induces SNAI-driven features of EMT in breast cancer.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting.

Genes·2026

Same author

Rapid Early Motor Improvement After Full Endoscopic Interlaminar Discectomy for L4-L5 Disc Herniation Presenting With Foot Drop: A Case Report.

Cureus·2026

Search research articles

Related Experiment Video

Updated: May 19, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

A case of hyperprolactinemia, probably induced by eletriptan.

Hakki Yilmaz¹, Mustafa Kaya, Mustafa Ozbek

¹Department of Endocrinology and Metabolism, Diskapi Yildirim Beyazit Education and Researching Hospital, Ankara, Turkey. drhakkiyilmaz@yahoo.com

International Journal of Clinical Pharmacology and Therapeutics

|September 5, 2012

Summary

Eletriptan, a migraine medication, may cause hyperprolactinemia, leading to irregular periods and milky nipple discharge. This is the first reported case linking eletriptan to these symptoms.

Related Experiment Videos

Last Updated: May 19, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

Area of Science:

Neurology
Endocrinology
Pharmacology

Background:

Migraine management often involves specific triptan agents.
Hyperprolactinemia is a condition characterized by elevated prolactin levels.
Oligomenorrhea and galactorrhea are potential clinical manifestations of hyperprolactinemia.

Observation:

A 25-year-old woman experienced oligomenorrhea and galactorrhea after initiating eletriptan therapy (40 mg/d) for severe migraine.
Other causes of hyperprolactinemia were systematically excluded.
The Naranjo probability scale suggested a probable association between eletriptan use and the observed symptoms.

Findings:

This case report details the first documented instance of eletriptan-induced hyperprolactinemia.
The patient presented with symptoms of oligomenorrhea and galactorrhea, consistent with elevated prolactin levels.
The temporal relationship and exclusion of other causes support a drug-induced etiology.

Implications:

Clinicians should be aware of the potential for eletriptan to cause hyperprolactinemia.
Monitoring for symptoms like oligomenorrhea and galactorrhea is crucial in patients taking eletriptan.
This finding highlights the importance of postmarketing surveillance for identifying rare adverse drug reactions.